Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
10 participants
INTERVENTIONAL
2017-10-25
2018-05-02
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Postprandial Plasma Amino Acid Concentrations After Dairy Consumption
NCT02546141
Real-time Amino Acid Profiling
NCT03547362
Postprandial Amino Acid Response After Protein Consumption
NCT04935788
Dairy and Plant Amino Acid Uptake. An Explorative Study
NCT05813769
Milk and Plant Protein Digestion
NCT06272331
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
BASIC_SCIENCE
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Whey protein concentrate
portion size that contains 25 g of protein, oral, single administration
Whey protein concentrate
see arm description
Yoghurt
portion size that contains 25 g of protein, oral, single administration
Yoghurt
see arm description
50%whey-50% casein (Standard)
portion size that contains 25 g of protein, oral, single administration
50%whey-50% casein (Standard)
see arm description
50%whey-50% casein (Alternative)
portion size that contains 25 g of protein, oral, single administration
50%whey-50% casein (Alternative)
see arm description
Micellar Casein Isolate- WPH
portion size that contains 25 g of protein, oral, single administration
Micellar Casein Isolate- WPH
see arm description
Micellar Casein Isolate - Na-caseinate
portion size that contains 25 g of protein, oral, single administration
Micellar Casein Isolate - Na-caseinate
see arm description
Micellar Casein Isolate
portion size that contains 25 g of protein, oral, single administration
Micellar Casein Isolate
see arm description
UHT milk
portion size that contains 25 g of protein, oral, single administration
UHT milk
see arm description
Recombined milk
portion size that contains 25 g of protein, oral, single administration
Recombined milk
see arm description
Recombined 50% whey milk
portion size that contains 25 g of protein, oral, single administration
Recombined 50%whey milk
see arm description
Ca-caseinate
portion size that contains 25 g of protein, oral, single administration
Ca-caseinate
see arm description
Milk protein isolate
portion size that contains 25 g of protein, oral, single administration
Milk protein isolate
see arm description
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Whey protein concentrate
see arm description
Yoghurt
see arm description
50%whey-50% casein (Standard)
see arm description
50%whey-50% casein (Alternative)
see arm description
Micellar Casein Isolate- WPH
see arm description
Micellar Casein Isolate - Na-caseinate
see arm description
Micellar Casein Isolate
see arm description
UHT milk
see arm description
Recombined milk
see arm description
Recombined 50%whey milk
see arm description
Ca-caseinate
see arm description
Milk protein isolate
see arm description
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* BMI 18.5-30 kg/m2
* Non-smoking
* Healthy as assessed by the NIZO lifestyle and health questionnaire ("Verklaring leefgewoonten en gezondheid") and according to the judgment of the study physician.".
* Regular and normal Dutch eating habits as assessed by the NIZO lifestyle and health questionnaire (3 main meals per day)
* Veins suitable for cannulation (blood sampling)
* Voluntary participation
* Having given written informed consent
* Willing to comply with study procedures
* Accept use of all encoded data, including publication, and the confidential use and storage of all data for 15 years.
* Accept disclosure of the financial benefit of participation in the study to the authorities concerned
Exclusion Criteria
* Having a history of medical or surgical events that may significantly affect the study outcome, including: Inflammatory bowel disease, hepatitis, pancreatitis, ulcers, gastrointestinal or rectal bleeding; major gastrointestinal tract surgery such as gastrectomy, gastroenterostomy, or bowel resection; known or suspected gastrointestinal disorders, colon or GI tract cancer
* Use of the following medication: glucose lowering drugs, insulin; medication that may impact gastric emptying (e.g. gastric acid inhibitors or laxatives)
* Diagnosed with diabetes, being treated for high blood glucose or increased fasting blood glucose (\> 7 mmol/l in finger prick blood) as assessed during screening visit
* For men: Hb \<8,5 mmol/l as assessed during screening visit; for women: Hb \<7,5 mmol/l.
* Use of protein supplements
* Mental status that is incompatible with the proper conduct of the study
* A self-reported reported food allergy or sensitivity to dairy ingredients
* Alcohol consumption for men \> 28 units/week and \>4/day; for women: \>21 units/week and \>3/day
* Reported weight loss or weight gain of \> 3 kg in the month prior to pre-study screening, or intention to lose weight during the study period
* Reported slimming or medically prescribed diet
* Recent blood donation (\<1 month prior to Day 01 of the study)
* Not willing or afraid to give up blood donation during the study
* Personnel of NIZO food research, FrieslandCampina Research, or Wageningen University, department of Human Nutrition, their partner and their first and second degree relatives
* Not having a general practitioner
* Not willing to accept information-transfer concerning participation in the study, or information regarding his/her health, like laboratory results and eventual adverse events to and from his general practitioner
* Self reported pregnancy or breastfeeding
18 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
FrieslandCampina
INDUSTRY
NIZO Food Research
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Alwine Kardinaal, PhD
Role: PRINCIPAL_INVESTIGATOR
NIZO Food Research
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
NIZO
Ede, , Netherlands
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NIZO175
Identifier Type: OTHER
Identifier Source: secondary_id
NL62458.072.17
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.